MGP
BIO icon

Metis Global Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

Metis Global Partners’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-831
Closed -$202K – 775
2025
Q1 		$202K Buy
831
+119
+17% +$35.8K 0.01% 731
2024
Q4 		$234K Buy
712
+30
+4% +$10.2K 0.01% 716
2024
Q3 		$228K Sell
682
-346
-34% -$110K 0.01% 712
2024
Q2 		$281K Sell
1,028
-20
-2% -$5.82K 0.01% 661
2024
Q1 		$362K Buy
1,048
+14
+1% +$4.6K 0.01% 626
2023
Q4 		$334K Sell
1,034
-48
-4% -$15K 0.01% 633
2023
Q3 		$388K Buy
1,082
+103
+11% +$39.7K 0.02% 583
2023
Q2 		$371K Buy
979
+86
+10% +$35K 0.02% 583
2023
Q1 		$428K Buy
893
+229
+34% +$107K 0.03% 516
2022
Q4 		$279K Buy
664
+166
+33% +$67K 0.02% 540
2022
Q3 		$208K Buy
498
+79
+19% +$39.4K 0.03% 496
2022
Q2 		$208K Buy
+419
New +$218K 0.03% 508

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
FPA
First Pacific Advisors El Segundo, California $8.09B AUM 21.95% 1-Year Est. Return

Metis Global Partners's BIO Position: Q2 2025 in Review

Metis Global Partners sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2025, closing a stake of 831 shares — an estimated $202K sold.

Metis Global Partners first reported a position in BIO in Q2 2022 and held it in 12 quarters. The position peaked at $428K in Q1 2023. 384 funds tracked by Wall St. Rank hold BIO as of Q2 2025.

  • Metis Global Partners reported no remaining Bio-Rad Laboratories Class A position as of Q2 2025 after selling out during the quarter.
  • Metis Global Partners sold 831 Bio-Rad Laboratories Class A shares in Q2 2025, an estimated $202K.
  • Metis Global Partners first reported a position in Bio-Rad Laboratories Class A in Q2 2022 and held it in 12 quarters.
  • Metis Global Partners's Bio-Rad Laboratories Class A position peaked at $428K in Q1 2023.
  • 384 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2025.

Based on Metis Global Partners's 13F filing for Q2 2025, filed 6 Aug 2025.